|
|
|
| Clinical Value of GD-EOB-DTPA Contrast-enhanced Imaging and DWI in the Diagnosis of Small Hepatocellular Carcinoma |
| ZENG Fei-xiang, MAO Si-xin, WU Wei-jun |
| Department of Radiology,Anting Hospital, Shanghai Jiading District, Shanghai 201805 |
|
|
|
|
Abstract 【Objective】Objective to investigate the value of contrast-enhanced and diffusion-weighted imaging (DWI) with liver cell specific contrast agent (GD-EOB-DTPA) in the diagnosis of small hepatocellular carcinoma (sHCC). 【Methods】The clinical data of 83 patients with suspected HCC diagnosed by ultrasound or CT from November 2016 to December 2020 were selected, All patients were diagnosed by GD-EOB-DTPA contrast-enhanced (hepatobiliary phase, portal phase and arterial phase) combined with DWI on the basis of conventional imaging. Taking the pathological results as the gold standard, the positive detection rates of sHCC by different imaging methods were compared according to the working characteristic curve (ROC) of the test results, and the accuracy was determined according to the area under the curve (AUC).【Results】 Fifty three of 83 patients were diagnosed as positive sHCC by pathological examination; The diagnostic results of GD-EOB-DTPA showed that there were 33 patients with positive sHCC and 20 patients with negative sHCC; The results of DWI showed that there were 34 patients with positive SHCC and 22 patients with negative SHCC; The diagnostic results of GD-EOB -DTPA combined with DWI showed that there were 45 patients with positive sHCC and 27 patients with negative sHCC (P<0.05); The positive detection rates of GD-EOB-DTPA and DWI were lower than those of GD-EOB-DTPA combined with DWI (P>0.05); the diagnostic AUC of GD- EOB-DTPA combined with DWI was 0.875, which was higher than that of GD-EOB-DTPA or DWI alone. 【Conclusion】 The combination of GD-EOB-DTPA contrast enhancement and DWI can effectively improve the positive detection rate of SHCC.
|
|
Received: 13 April 2021
|
|
|
|
|
|
[1] 万丛超,陈印.雷替曲塞结合介入疗法在中晚期肝细胞癌患者中的应用效果[J].医学临床研究,2020,37(4):606-608.
[2] RIMOLA J, FORNER A, SAPENA V, et al. Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma[J].Eur Radiol,2020,30(1):186-194.
[3] KIM J W, LEE C H, KIM S B, et al. Washout appearance in Gd-EOB-DTPA-enhanced MR imaging: A differentiating feature between hepatocellular carcinoma with paradoxical uptake on the hepatobiliary phase and focal nodular hyperplasia-like nodules[J].J Magn Reson Imaging,2017,45(6):1599.
[4] YANG H J, SONG J S, CHOI E J, et al. Hypovascular hypointense nodules in hepatobiliary phase without T2 hyperintensity: long-term outcomes and added value of DWI in predicting hypervascular transformation[J].Clin Imaging,2018,50(1):123-129.
[5] 武靖,康钰,洪楠, 等.Gd-EOB-DTPA肝胆期MRI结合DWI对原发性肝细胞癌的检出价值[J].第三军医大学学报,2015,37(6):548-552.
[6] 中国医师协会介入医师分会.中国肝细胞癌经动脉化疗栓塞治疗(TACE)临床实践指南[J].介入放射学杂志,2018,27(12):1117-1126.
[7] 刘文平.整合素 α5 和 caspase3 在肝细胞癌中的表达情况及意义[J].医学临床研究,2019,36(4):689-692.
[8] 吕佳昱.《2018年欧洲肿瘤内科学会临床实践指南:肝细胞癌的诊断、治疗和随访》摘译[J].临床肝胆病杂志,2019,35(4):766-768.
[9] LEE M W, LIM H K. Management of sub-centimeter recurrent hepatocellular carcinoma after curative treatment: Current status and future[J].World J Gastroenterol,2018,24(46):5215-5222.
[10] 刘海峰,许永生,刘钊, 等.钆塞酸二钠增强磁共振和弥散加权成像诊断肝细胞癌TACE术后存活或复发病灶的价值[J].中国医学物理学杂志,2020,37(5):561-567.
[11] 杨健,柏玉涵,时昭红, 等.Gd-EOB-DTPA多模态MRI对常规MRI不典型强化肝硬化结节的诊断价值[J].中国医学影像学杂志,2019,27(9):695-699.
[12] 孙玉,张楠,侯洁, 等.钆塞酸二钠MRI对肝细胞癌的诊断价值[J].临床肝胆病杂志,2018,34(1):129-132.
[13] 许永生,刘海峰,黎金葵, 等.Gd-EOB-DTPA增强MRI鉴别肝脏良恶性病灶的临床应用价值[J].磁共振成像,2018,9(7):506-511.
[14] 郑泽宇,许乙凯,张静, 等.钆塞酸二钠及灌注加权成像在肝癌化疗栓塞术后的应用[J].实用医学杂志,2016,32(9):1455-1457.
[15] 蔡健华,王秀彬,陆健, 等.对比钆塞酸二钠增强MR检查中短反转时间反转恢复序列与化学位移选择序列DWI检出肝细胞癌[J].中国医学影像技术,2019,35(11):1737-1742. |
| [1] |
. [J]. JOURNAL OF CLINICAL RESEARCH, 2021, 38(9): 1410-1412. |
|
|
|
|
2021, Vol. 38 
